Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Revenue of Travere Therapeutics, Inc. (TVTX)
Revenue in 2023 (TTM): $145.24 M
According to Travere Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $145.24 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Travere Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $145.24 M | $133.79 M | $-326,246,000 | $-376,110,000 | $-111,399,000 |
| 2022 | $212.02 M | $204.43 M | $-299,422,000 | $-278,169,000 | $-278,482,000 |
| 2021 | $227.49 M | $220.71 M | $-186,679,000 | $-179,682,000 | $-180,091,000 |
| 2020 | $198.32 M | $192.2 M | $-143,952,000 | $-188,790,000 | $-169,431,000 |
| 2019 | $175.34 M | $170.1 M | $-107,213,000 | $-146,448,000 | $-146,427,000 |
| 2018 | $164.25 M | $158.72 M | $-73,389,000 | $-101,867,000 | $-102,678,000 |
| 2017 | $154.94 M | $151.33 M | $-38,671,000 | $-58,363,000 | $-59,731,000 |
| 2016 | $133.59 M | $129.04 M | $-38,788,000 | $-57,582,000 | $-47,903,000 |
| 2015 | $99.89 M | $97.71 M | $129.46 M | $105.47 M | $117.24 M |
| 2014 | $28.2 M | $27.63 M | $-74,107,000 | $-113,397,610 | $-110,937,862 |
| 2013 | $ | $ | $-34,286,771 | $-33,747,734 | $-33,823,509 |
| 2012 | $ | $ | $-30,113,052 | $-30,343,856 | $-30,343,856 |
| 2011 | $ | $ | $-12,825 | $-14,825 | $-14,825 |
| 2010 | $ | $ | $ | $ | $ |
| 2009 | $ | $ | $ | $ | $ |
| 2008 | $ | $ | $-18,266 | $-18,266 | $-18,266 |